Martin Lagging

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6221535/publications.pdf

Version: 2024-02-01

113 papers	4,872 citations	136950 32 h-index	98798 67 g-index
113 all docs	113 docs citations	113 times ranked	5084 citing authors

#	Article	IF	Citations
1	Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2â€“Specific T Cells in Whole Blood. Journal of Infectious Diseases, 2022, 226, 208-216.	4.0	9
2	Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. Blood Advances, 2022, 6, 2723-2730.	5.2	19
3	Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation. Haematologica, 2022, 107, 1479-1482.	3.5	15
4	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	8.1	237
5	Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination. JHEP Reports, 2022, 4, 100496.	4.9	14
6	Transient and durable T cell reactivity after COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	7
7	The case for simplifying and using absolute targets for viral hepatitis elimination goals. Journal of Viral Hepatitis, 2021, 28, 12-19.	2.0	28
8	Surveillance of wastewater revealed peaks of SARS-CoV-2 preceding those of hospitalized patients with COVID-19. Water Research, 2021, 189, 116620.	11.3	112
9	Absence of interferon-Î» 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection. Scandinavian Journal of Gastroenterology, 2021, 56, 855-861.	1.5	0
10	Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVIDâ€19. Liver International, 2021, 41, 2024-2031.	3.9	9
11	Presence of interferon-Î» 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. Scandinavian Journal of Gastroenterology, 2021, 56, 849-854.	1.5	1
12	Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study. BMJ Open, 2020, 10, e035996.	1.9	1
13	The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection. PLoS ONE, 2020, 15, e0237840.	2.5	4
14	The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. Scandinavian Journal of Gastroenterology, 2019, 54, 1172-1175.	1.5	1
15	Hepatitis E virus genotype 3 is associated with gallstone-related disease. Scandinavian Journal of Gastroenterology, 2019, 54, 1269-1273.	1.5	3
16	Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study. Journal of Neurology, 2019, 266, 2208-2215.	3.6	2
17	Ribavirin: pharmacology, multiple modes of action and possible future perspectives. Future Virology, 2019, 14, 153-160.	1.8	53
18	No need to discontinue hepatitis C virus therapy at the time of liver transplantation. PLoS ONE, 2019, 14, e0211437.	2.5	4

#	Article	IF	Citations
19	Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden. Infectious Diseases, 2019, 51, 131-139.	2.8	12
20	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. Infectious Diseases, 2018, 50, 569-583.	2.8	20
21	PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology, 2018, 53, 83-87.	1.5	19
22	Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus. Journal of Virology, 2018, 92, .	3.4	18
23	Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PLoS ONE, 2018, 13, e0198296.	2.5	2
24	High seroprevalence against hepatitis E virus in patients with chronic hepatitis C virus infection. Journal of Clinical Virology, 2017, 88, 39-45.	3.1	18
25	Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection. Journal of Hepatology, 2017, 67, 649-651.	3.7	5
26	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 325-336.	8.1	208
27	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. Infectious Diseases, 2017, 49, 561-575.	2.8	14
28	Editorial: ribavirin continues to play a role in treatment with directâ€acting antivirals for hepatitis C virusâ€infected patients with decompensated cirrhosis. Alimentary Pharmacology and Therapeutics, 2017, 46, 1115-1116.	3.7	4
29	Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scandinavian Journal of Gastroenterology, 2017, 52, 61-68.	1.5	12
30	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infectionsâ€"A Scandinavian real-life study. PLoS ONE, 2017, 12, e0179764.	2.5	28
31	Imported Case of Lassa Fever in Sweden With Encephalopathy and Sensorineural Hearing Deficit. Open Forum Infectious Diseases, 2016, 3, ofw198.	0.9	23
32	Grazoprevir plus peginterferon and ribavirin in treatmentâ€naive patients with hepatitis C virus genotype 1 infection: a randomized trial. Journal of Viral Hepatitis, 2016, 23, 80-88.	2.0	14
33	Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scandinavian Journal of Gastroenterology, 2016, 51, 337-343.	1.5	13
34	Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. Infectious Diseases, 2016, 48, 251-261.	2.8	12
35	Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study. Journal of Clinical Microbiology, 2016, 54, 549-555.	3.9	94
36	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. PLoS ONE, 2016, 11, e0155142.	2.5	10

#	Article	IF	Citations
37	Chronic hepatitis E infection with an emerging virus strain in a heart transplant recipient successfully treated with ribavirin: a case report. Journal of Medical Case Reports, 2015, 9, 180.	0.8	11
38	Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics, 2015, 16, 1179-1188.	1.3	24
39	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet, The, 2015, 385, 1075-1086.	13.7	281
40	A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis. PLoS ONE, 2014, 9, e93601.	2.5	6
41	Do variations in the ITPA gene determine the risk of hepatitis C virus relapse?. Future Microbiology, 2014, 9, 1009-1012.	2.0	3
42	Chronic hepatitis C in Swedish subjects receiving opiate substitution therapyâ€"Factors associated with advanced fibrosis. Scandinavian Journal of Infectious Diseases, 2014, 46, 340-347.	1.5	4
43	Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities â€“ completion rates and efficacy. European Journal of Gastroenterology and Hepatology, 2014, 26, 523-531.	1.6	10
44	Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology, 2014, 59, 2131-2139.	7.3	38
45	The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Alimentary Pharmacology and Therapeutics, 2014, 39, 322-330.	3.7	21
46	Elevated antibody reactivity to measles virus NCORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production. Journal of Clinical Virology, 2014, 61, 107-112.	3.1	8
47	Reply. Hepatology, 2014, 60, 2130-2131.	7.3	0
48	Intrahepatic <scp>mRNA</scp> levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C. Liver International, 2013, 33, 94-103.	3.9	5
49	Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scandinavian Journal of Gastroenterology, 2013, 48, 839-847.	1.5	15
50	Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in Sweden. Scandinavian Journal of Infectious Diseases, 2013, 45, 796-799.	1.5	7
51	Dynamic tailoring of treatment durations improves efficiency of hepatitis <scp>C</scp> treatment with pegylated interferon and ribavirin. Journal of Viral Hepatitis, 2013, 20, e82-9.	2.0	1
52	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. PLoS ONE, 2013, 8, e56991.	2.5	12
53	Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Transient Elastography in Chronic Hepatitis C Infection. PLoS ONE, 2013, 8, e80172.	2.5	22
54	Impact of donor histology on survival following liver transplantation for chronic hepatitis C virus infection: A Scandinavian single-center experience. Scandinavian Journal of Gastroenterology, 2012, 47, 710-717.	1.5	7

#	Article	IF	Citations
55	Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes. Pharmacogenomics, 2012, 13, 847-849.	1.3	7
56	Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3. PLoS ONE, 2012, 7, e29370.	2.5	32
57	Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. Scandinavian Journal of Infectious Diseases, 2012, 44, 502-521.	1.5	13
58	PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Medical Genetics, 2012, 13, 82.	2.1	21
59	Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1631-1635.	2.9	8
60	The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1â€“infected patients treated with Pegâ€IFNâ€alfaâ€2a and ribavirin. Journal of Viral Hepatitis, 2012, 19, 488-496.	2.0	9
61	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterology, 2012, 12, 11.	2.0	30
62	Impact of Obesity on the Bioavailability of Peginterferon-Î±2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. PLoS ONE, 2012, 7, e37521.	2.5	19
63	Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden. Scandinavian Journal of Infectious Diseases, 2011, 43, 522-527.	1.5	9
64	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. Journal of Hepatology, 2011, 55, 980-988.	3.7	97
65	Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?. Journal of Hepatology, 2011, 54, 835-836.	3.7	8
66	IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2011, 33, 1162-1172.	3.7	83
67	Are FoxP3+ cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?. Journal of Viral Hepatitis, 2011, 18, 149-151.	2.0	1
68	Hepatitis C treatment response kinetics and impact of baseline predictors. Journal of Viral Hepatitis, 2011, 18, 400-407.	2.0	11
69	IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. Journal of Viral Hepatitis, 2011, 18, e325-31.	2.0	52
70	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International, 2011, 31, 30-60.	3.9	333
71	Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus. Journal of Infectious Diseases, 2011, 203, 1748-1752.	4.0	45
72	Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. Journal of Viral Hepatitis, 2011, 18, 245-251.	2.0	24

#	Article	IF	Citations
73	Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infectious Diseases, 2011, 11, 124.	2.9	37
74	Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. Hepatology, 2011, 53, 1067-1068.	7.3	4
75	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. PLoS ONE, 2011, 6, e17232.	2.5	131
76	Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology, 2010, 51, 1523-1530.	7.3	105
77	Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology, 2010, 52, 430-435.	7.3	82
78	Observed and calculated interleukin-28B genotype frequencies in hepatitis C virus infection. Hepatology, 2010, 52, 1860-1861.	7.3	3
79	Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?. Clinical Infectious Diseases, 2010, 50, e22-e25.	5.8	2
80	IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. Scandinavian Journal of Infectious Diseases, 2010, 42, 896-901.	1.5	27
81	A Model Explaining the Correlations Between IL28B-Related Genotypes, Hepatitis C Virus Genotypes, and Viral RNA Levels. Gastroenterology, 2010, 139, 1794-1796.	1.3	15
82	Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations. Scandinavian Journal of Infectious Diseases, 2009, 41, 389-402.	1.5	21
83	Randomized comparison of 12 or 24 weeks of peginterferon Î±-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology, 2008, 47, 1837-1845.	7.3	196
84	Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology, 2008, 48, 695-695.	7.3	13
85	A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scandinavian Journal of Gastroenterology, 2008, 43, 73-80.	1.5	29
86	Acute exacerbation of chronic hepatitis B: Yet another incentive to commence universal infant immunization even in low endemic areas. Scandinavian Journal of Gastroenterology, 2008, 43, 131-131.	1.5	0
87	Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection. Journal of Clinical Microbiology, 2007, 45, 2439-2445.	3.9	16
88	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). Gastroenterology, 2007, 133, 1132-1143.	1.3	57
89	Predicting treatment outcome following 24 weeks peginterferon Î±-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. Hepatology, 2007, 45, 258-259.	7.3	6
90	Impact of disease severity on outcome of antiviral therapy in treatment-naÃ¯ve patients with chronic hepatitis C. Hepatology, 2007, 45, 1333-1334.	7.3	3

#	Article	IF	Citations
91	Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. Journal of Viral Hepatitis, 2007, 14, 29-35.	2.0	70
92	Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. Journal of Hepatology, 2006, 45, 539-546.	3.7	76
93	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology, 2006, 44, 1617-1625.	7.3	193
94	Interferon (IFN)â€“Î³â€“Inducible Proteinâ€“10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFNâ€Î±2a and Ribavirin for Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2006, 194, 895-903.	4.0	201
95	Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scandinavian Journal of Gastroenterology, 2005, 40, 867-872.	1.5	127
96	Monitoring treatment response by the hepatitis C virus core antigen assay. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 230-232.	2.9	1
97	Indeterminate third-generation hepatitis C recombinant immunoblot assay and HCV RNA analysis: Isolated reactivity against NS5 associated with HCV viraemia in clinical patients but not blood donors. Scandinavian Journal of Infectious Diseases, 2005, 37, 488-492.	1.5	12
98	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. Journal of Hepatology, 2005, 43, 250-257.	3.7	143
99	Complement-Mediated Enhancement of Antibody Function for Neutralization of Pseudotype Virus Containing Hepatitis C Virus E2 Chimeric Glycoprotein. Journal of Virology, 2002, 76, 2150-2158.	3.4	43
100	Neutralization of Pseudotyped Vesicular Stomatitis Virus Expressing Hepatitis C Virus Envelope Glycoprotein 1 or 2 by Serum from Patients. Journal of Infectious Diseases, 2002, 185, 1165-1169.	4.0	21
101	Comparison of Serum Hepatitis C Virus RNA and Core Antigen Concentrations and Determination of Whether Levels Are Associated with Liver Histology or Affected by Specimen Storage Time. Journal of Clinical Microbiology, 2002, 40, 4224-4229.	3.9	26
102	Nosocomial Transmission of HCV in a Cardiology Ward During the Window Phase of Infection: An Epidemiological and Molecular Investigation. Scandinavian Journal of Infectious Diseases, 2002, 34, 580-582.	1.5	38
103	Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. Journal of Hepatology, 2002, 37, 837-842.	3.7	245
104	Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver, 2002, 22, 136-144.	0.1	69
105	Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. Journal of Viral Hepatitis, 2002, 9, 235-241.	2.0	128
106	Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus. Virus Research, 2001, 75, 147-154.	2.2	13
107	Monitoring Virological Responses to Interferon-Ribavirin and Interferon Monotherapy of Chronic Hepatitis C Re-treated due to Relapse or Non-response. Scandinavian Journal of Infectious Diseases, 2001, 33, 110-115.	1.5	3
108	Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver International, 1999, 19, 183-187.	3.9	182

#	Article	IF	Citations
109	Chronic Hepatitis C in Sweden: Genotype Distribution Over Time in Different Epidemiological Settings. Scandinavian Journal of Infectious Diseases, 1999, 31, 355-358.	1.5	25
110	Functional Role of Hepatitis C Virus Chimeric Glycoproteins in the Infectivity of Pseudotyped Virus. Journal of Virology, 1998, 72, 3539-3546.	3.4	97
111	Delayed Treatment of Pulmonary Blastomycosis Causing Vertebral Osteomyelitis, Paraspinal Abscess, and Spinal Cord Compression. Scandinavian Journal of Infectious Diseases, 1994, 26, 111-115.	1.5	19
112	Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. Journal of Virology, 1994, 68, 4420-4426.	3.4	47
113	Evaluation of QuickVue, a rapid enzyme immunoassay test for the detection of serum antibodies to Helicobacter pylori. Diagnostic Microbiology and Infectious Disease, 1993, 16, 317-320.	1.8	24